TWI592173B - Wet wound dressing - Google Patents
Wet wound dressing Download PDFInfo
- Publication number
- TWI592173B TWI592173B TW105102408A TW105102408A TWI592173B TW I592173 B TWI592173 B TW I592173B TW 105102408 A TW105102408 A TW 105102408A TW 105102408 A TW105102408 A TW 105102408A TW I592173 B TWI592173 B TW I592173B
- Authority
- TW
- Taiwan
- Prior art keywords
- hydrophilic polyurethane
- wound dressing
- polyether polyol
- wound
- wet wound
- Prior art date
Links
- 239000004814 polyurethane Substances 0.000 claims description 44
- 229920002635 polyurethane Polymers 0.000 claims description 43
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 33
- 229920000570 polyether Polymers 0.000 claims description 33
- 229920005862 polyol Polymers 0.000 claims description 33
- 150000003077 polyols Chemical class 0.000 claims description 33
- 229920005830 Polyurethane Foam Polymers 0.000 claims description 28
- 239000011496 polyurethane foam Substances 0.000 claims description 28
- 238000005187 foaming Methods 0.000 claims description 19
- 239000011148 porous material Substances 0.000 claims description 18
- 239000005056 polyisocyanate Substances 0.000 claims description 17
- 229920001228 polyisocyanate Polymers 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 238000010521 absorption reaction Methods 0.000 claims description 9
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- -1 poly(propylene glycol) Polymers 0.000 claims description 6
- 229920000768 polyamine Polymers 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 4
- 230000002745 absorbent Effects 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000004604 Blowing Agent Substances 0.000 claims description 3
- 206010052428 Wound Diseases 0.000 description 84
- 208000027418 Wounds and injury Diseases 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 10
- 229920002674 hyaluronan Polymers 0.000 description 10
- 229960003160 hyaluronic acid Drugs 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 6
- 206010072170 Skin wound Diseases 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 3
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- SVYKKECYCPFKGB-UHFFFAOYSA-N N,N-dimethylcyclohexylamine Chemical compound CN(C)C1CCCCC1 SVYKKECYCPFKGB-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 2
- UKODFQOELJFMII-UHFFFAOYSA-N pentamethyldiethylenetriamine Chemical compound CN(C)CCN(C)CCN(C)C UKODFQOELJFMII-UHFFFAOYSA-N 0.000 description 2
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 2
- WTFAGPBUAGFMQX-UHFFFAOYSA-N 1-[2-[2-(2-aminopropoxy)propoxy]propoxy]propan-2-amine Chemical compound CC(N)COCC(C)OCC(C)OCC(C)N WTFAGPBUAGFMQX-UHFFFAOYSA-N 0.000 description 1
- PAUHLEIGHAUFAK-UHFFFAOYSA-N 1-isocyanato-1-[(1-isocyanatocyclohexyl)methyl]cyclohexane Chemical compound C1CCCCC1(N=C=O)CC1(N=C=O)CCCCC1 PAUHLEIGHAUFAK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000011176 biofiber Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 201000000464 cone-rod dystrophy 2 Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- ADJMNWKZSCQHPS-UHFFFAOYSA-L zinc;6-methylheptanoate Chemical compound [Zn+2].CC(C)CCCCC([O-])=O.CC(C)CCCCC([O-])=O ADJMNWKZSCQHPS-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Description
本發明係關於一種創傷敷料,特別是關於一種由親水性聚氨酯發泡體形成的溼式創傷敷料。 The present invention relates to a wound dressing, and more particularly to a wet wound dressing formed from a hydrophilic polyurethane foam.
創傷敷料是以具有保持適當的溼潤環境、避免干擾生長、預防疤痕產生、防止傷口沾黏以及浸潤的特性為理想的創傷敷料。尤其是,當傷口保持在適當的溼潤環境時,能使纖維母細胞快速移動以加速微血管生成,並且能藉由自傷口滲出的組織液中含有的大量膠原蛋白及生長因子促進細胞的生長而加速傷口的癒合。此外,由於理想的創傷敷料不需要經常更換,因此傷口能保持在密閉、溼潤卻透氣的環境,不會受到外來細菌的感染的同時,能達到自體清創的效果。 Wound dressings are ideal wound dressings that have the characteristics of maintaining a proper moist environment, avoiding interference with growth, preventing scarring, preventing wound sticking and infiltration. In particular, when the wound is kept in a proper moist environment, the fibroblast can be rapidly moved to accelerate microvascular production, and the wound can be accelerated by promoting the growth of the cells by a large amount of collagen and growth factors contained in the tissue fluid exuded from the wound. Healing. In addition, since the ideal wound dressing does not need to be replaced frequently, the wound can be kept in a closed, moist, and breathable environment, and can be infected by foreign bacteria, and can achieve the effect of self-debridement.
然而,以自然癒合、使用紗布或棉墊等習知方式皆容易因接觸空氣而造成傷口表面乾燥,使纖維母細胞無法移動且減少組織液的滲出量,不僅延緩傷口癒合,還容易產生疤痕。並且,紗布等創傷敷料經常在更換時,將已癒合好的組織一併撕開,因而非常不利於傷口的復原。為了使傷口保持在溼潤環境且避免傷口的沾黏,進而發展出人上皮及泡棉等傷口敷料。然而,人上皮容易因吸水性不佳,使傷口浸泡在組織液中而造成浸潤。另一方面,雖然泡棉具有較佳的吸水性且能保持在溼潤環境,卻有因為孔徑較大而容易沾黏傷口的 問題。故,上述敷料皆無法具備理想的創傷敷料的特性而必須經常更換,進而增加傷口受到細菌或病毒感染的風險性,並且無法加速傷口癒合。 However, in the conventional way of natural healing, using gauze or cotton pad, it is easy to dry the wound surface due to contact with air, so that the fibroblast can not move and reduce the amount of exudation of the tissue fluid, which not only delays wound healing, but also easily causes scarring. Moreover, the wound dressing such as gauze often tears the healed tissue together when it is replaced, which is very disadvantageous for the recovery of the wound. In order to keep the wound in a humid environment and avoid the adhesion of the wound, a wound dressing such as human epithelium and foam is developed. However, the human epithelium is liable to cause infiltration by soaking the wound in the tissue fluid due to poor water absorption. On the other hand, although the foam has better water absorption and can be kept in a humid environment, it is easy to stick to the wound because of the large pore size. problem. Therefore, none of the above dressings can have the characteristics of an ideal wound dressing and must be replaced frequently, thereby increasing the risk of the wound being infected by bacteria or viruses and failing to accelerate wound healing.
有鑑於上述習知技藝之問題,本發明之目的是在提供一種溼式創傷敷料,以解決習知技術的敷料無法兼具透氣性、吸水性、保溼性以及防止傷口沾黏的特性,進而必須經常更換敷料的問題。 In view of the above-mentioned problems of the prior art, it is an object of the present invention to provide a wet wound dressing to solve the problem that the dressing of the prior art cannot combine the breathability, the water absorption, the moisture retention, and the prevention of the wound adhesion. The problem of dressing must be changed frequently.
根據本發明之一態樣,提出一種溼式創傷敷料,其由親水性聚氨酯發泡體形成,親水性聚氨酯發泡體係由一親水性聚氨酯與發泡組分發泡而形成。其中,親水性聚氨酯係由第一聚醚多元醇與多異氰酸酯反應,接著與第二聚醚多元醇反應而形成星狀(star)聚氨酯,其中第一聚醚多元醇係含有至少三個末端羥基。並且,親水性聚氨酯發泡體的孔洞係為非連續式的封閉孔洞。 According to an aspect of the present invention, a wet wound dressing comprising a hydrophilic polyurethane foam formed by foaming a hydrophilic polyurethane and a foaming component is proposed. Wherein the hydrophilic polyurethane is reacted with the first polyether polyol and the polyisocyanate, and then reacted with the second polyether polyol to form a star polyurethane, wherein the first polyether polyol contains at least three terminal hydroxyl groups. . Further, the pores of the hydrophilic polyurethane foam are discontinuous closed pores.
此外,根據本發明之另一態樣,提出一種親水性聚氨酯,其係將第一聚醚多元醇與多異氰酸酯反應,接著與第二聚醚多元醇及透明質酸反應而得的星狀嵌段(block)聚氨酯,其中,第一聚醚多元醇含有至少三個末端羥基。 Further, according to another aspect of the present invention, there is provided a hydrophilic polyurethane which is obtained by reacting a first polyether polyol with a polyisocyanate, followed by reaction with a second polyether polyol and hyaluronic acid. A block polyurethane wherein the first polyether polyol contains at least three terminal hydroxyl groups.
較佳地,多異氰酸酯可為脂肪族多異氰酸酯。 Preferably, the polyisocyanate can be an aliphatic polyisocyanate.
較佳地,發泡組分可包含發泡劑、水、界面活性劑、多胺及催化劑。 Preferably, the foaming component may comprise a blowing agent, water, a surfactant, a polyamine, and a catalyst.
較佳地,透明質酸的重量平均分子量範圍可為500,000~2,500,000。 Preferably, the hyaluronic acid has a weight average molecular weight ranging from 500,000 to 2,500,000.
較佳地,透明質酸的含量範圍可佔第一聚醚多元醇、多異氰酸酯、第二聚醚多元醇及透明質酸的總量之0.001~20mol%,更佳地,透明質酸的含量範圍可佔上述總量之0.001~10%。 Preferably, the content of hyaluronic acid may range from 0.001 to 20 mol% of the total amount of the first polyether polyol, the polyisocyanate, the second polyether polyol, and the hyaluronic acid, and more preferably, the content of hyaluronic acid. The range can be 0.001~10% of the total amount mentioned above.
較佳地,第一聚醚多元醇可為聚(丙二醇)三醇(Polypropylene glycol triol,PPG triol)。 Preferably, the first polyether polyol may be a polypropylene glycol triol (PPG triol).
較佳地,第二聚醚多元醇可為聚乙二醇(Polyethylene glycol,PEG)。 Preferably, the second polyether polyol may be polyethylene glycol (PEG).
較佳地,聚乙二醇的重量平均分子量範圍可為1,000~6,000。 Preferably, the polyethylene glycol has a weight average molecular weight ranging from 1,000 to 6,000.
較佳地,多異氰酸酯的含量範圍可佔親水性聚氨酯的20~70mol%。 Preferably, the polyisocyanate is present in an amount ranging from 20 to 70 mol% of the hydrophilic polyurethane.
較佳地,親水性聚氨酯發泡體中的第一聚醚多元醇與第二聚醚多元醇的含量範圍可佔親水性聚氨酯的20~70mol%。 Preferably, the content of the first polyether polyol and the second polyether polyol in the hydrophilic polyurethane foam may range from 20 to 70 mol% of the hydrophilic polyurethane.
較佳地,親水性聚氨酯發泡體可包含接觸層與吸收層,且接觸層與吸收層係為一體成形,其中接觸層可具有複數個第一孔洞,且吸收層可具有大於複數個第一孔洞的複數個第二孔洞。 Preferably, the hydrophilic polyurethane foam may comprise a contact layer and an absorbing layer, and the contact layer and the absorbing layer are integrally formed, wherein the contact layer may have a plurality of first holes, and the absorbing layer may have more than a plurality of first a plurality of second holes in the hole.
較佳地,本發明之溼式創傷敷料可進一步包含透氣層,係由親水性聚氨酯形成,其位在吸收層的一面上,透氣層中的第一聚醚多元醇與第二聚醚多元醇的含量範圍可佔親水性聚氨酯的20~70mol%。 Preferably, the wet wound dressing of the present invention may further comprise a gas permeable layer formed of a hydrophilic polyurethane on one side of the absorbent layer, the first polyether polyol and the second polyether polyol in the gas permeable layer. The content may range from 20 to 70 mol% of the hydrophilic polyurethane.
較佳地,接觸層可在形成親水性聚氨酯發泡體時,在親水性聚氨酯發泡體的表面進行刮動,接著施加一預定壓力所形成。 Preferably, the contact layer may be formed by scraping a surface of the hydrophilic polyurethane foam while forming a hydrophilic polyurethane foam, followed by applying a predetermined pressure.
較佳地,預定壓力的範圍係在100~300g/cm2。 Preferably, the predetermined pressure is in the range of 100 to 300 g/cm 2 .
綜上所述,本發明之溼式創傷敷料具有一或多個下述之優點: In summary, the wet wound dressing of the present invention has one or more of the following advantages:
(1)透氣性:由於本發明之溼式創傷敷料中的親水性聚氨酯同時具有親水端及疏水端,使分子之間產生排斥而彼此不會交聯(cross-link),因此在分子之間具有微小空隙,藉此達到透氣的效果。 (1) Gas permeability: Since the hydrophilic polyurethane in the wet wound dressing of the present invention has both a hydrophilic end and a hydrophobic end, the molecules are repelled and do not cross-link with each other, so It has a small gap to achieve a breathable effect.
(2)吸水性:本發明之溼式創傷敷料藉由星狀聚氨酯具有比表面積較大的星狀結構,以提升創傷敷料的吸水性,因此能吸收過多的組織液而避免細胞浸潤。 (2) Water Absorption: The wet wound dressing of the present invention has a star-shaped structure having a large specific surface area by star-shaped polyurethane to enhance the water absorption of the wound dressing, thereby absorbing too much tissue fluid and avoiding cell infiltration.
(3)防止傷口沾黏:本發明之溼式創傷敷料藉由非連續式的封閉孔洞,使增生的細胞不會進入接觸層,並藉由材料中的聚乙二醇具有抗蛋白質及細胞貼附的特性,更能防止傷口的沾黏。 (3) Prevention of wound sticking: The wet wound dressing of the present invention prevents the proliferating cells from entering the contact layer by discontinuously closing the pores, and has anti-protein and cell paste by the polyethylene glycol in the material. The attached features are more resistant to the adhesion of the wound.
100‧‧‧親水性聚氨酯發泡體 100‧‧‧Hydrophilic polyurethane foam
110‧‧‧接觸層 110‧‧‧Contact layer
111‧‧‧第一孔洞 111‧‧‧First hole
120‧‧‧吸收層 120‧‧‧absorbing layer
121‧‧‧第二孔洞 121‧‧‧Second hole
200‧‧‧透氣層 200‧‧‧ breathable layer
300‧‧‧背襯 300‧‧‧Backing
301‧‧‧離型紙 301‧‧‧ release paper
S‧‧‧皮膚 S‧‧‧ skin
W‧‧‧傷口 W‧‧‧Wound
第1圖係為本發明之溼式創傷敷料的第一實施例之示意圖。 Figure 1 is a schematic illustration of a first embodiment of a wet wound dressing of the present invention.
第2圖係為本發明之溼式創傷敷料的第一實施例之操作示意圖。 Figure 2 is a schematic illustration of the operation of the first embodiment of the wet wound dressing of the present invention.
第3圖係為本發明之溼式創傷敷料的第二實施例運用於傷口之截面圖。 Figure 3 is a cross-sectional view of a second embodiment of the wet wound dressing of the present invention applied to a wound.
第4圖至第6圖係為形成第3圖所示第二實施例的階段之截面圖。 4 to 6 are cross-sectional views showing the stage of the second embodiment shown in Fig. 3.
為利 貴審查員瞭解本發明之技術特徵、內容與優點及其所能達成之功效,茲將本發明配合附圖,並以實施例之表達形式詳細說明如下,而其中所使用之圖式,其主旨僅為示意及輔助說明之用,未必為本發明實施後之真實比例與精準配置,故不應就所附之圖式的比例與配置關係解讀、侷限本發明於實際實施上的權利範圍,合先敘明。 The technical features, contents, and advantages of the present invention, as well as the advantages thereof, can be understood by the present inventors, and the present invention will be described in detail with reference to the accompanying drawings. The subject matter is only for the purpose of illustration and description, and is not necessarily the true proportion and precise configuration after the implementation of the present invention. Therefore, the scope and configuration relationship of the attached drawings should not be interpreted or limited. First described.
以下將參照相關圖式,說明依本發明之溼式創傷敷料之實施例,為使便於理解,下述實施例中之相同元件係以相同之符號標示來說明。 The embodiments of the wet wound dressing according to the present invention will be described below with reference to the related drawings. For ease of understanding, the same elements in the following embodiments are denoted by the same reference numerals.
請一併參照第1圖及第2圖,第1圖及第2圖係為本發明之溼式創傷敷料的第一實施例之示意圖及操作示意圖。在本發明的第一實施例中,溼式創 傷敷料係由親水性聚氨酯發泡體100形成,但不限於此,亦可不經發泡而直接由親水性聚氨酯形成。該親水性聚氨酯是將包含至少三個末端羥基的第一聚醚多元醇,其較佳為聚(丙二醇)三醇與多異氰酸酯反應以延伸形成星狀預聚物,接著再將星狀預聚物與第二聚醚多元醇,其較佳為聚二乙醇及透明質酸進行交聯反應而得的星狀嵌段聚氨酯。 Please refer to FIG. 1 and FIG. 2 together. FIG. 1 and FIG. 2 are schematic diagrams and operation diagrams of the first embodiment of the wet wound dressing of the present invention. In the first embodiment of the invention, the wet wound The wound dressing is formed of the hydrophilic polyurethane foam 100, but is not limited thereto, and may be directly formed of a hydrophilic polyurethane without foaming. The hydrophilic polyurethane is a first polyether polyol comprising at least three terminal hydroxyl groups, preferably poly(propylene glycol) triol is reacted with a polyisocyanate to extend to form a star prepolymer, followed by star prepolymerization. And a second polyether polyol, which is preferably a star-shaped block polyurethane obtained by crosslinking a polydiethanol and a hyaluronic acid.
其中,多異氰酸酯較佳為脂肪族多異氰酸酯,以避免選自芳香族化合物可能具有的毒性風險,且更佳地,該脂肪族多異氰酸酯可選自於1,6-己二異氰酸酯(hexamethylene diisocyanate,HDI)、伸甲基二環己基二異氰酸酯(methylene dicyclohexyl diisocyanate,H12 MDI)、異佛酮二異氰酸酯(isophorone diisocyanate,IPDI)或其組合。此外,聚二乙醇的重量平均分子量範圍較佳為1,000~6,000。若聚乙二醇的重量平均分子量小於1,000時,會經由代謝產生生物毒性;若聚乙二醇的重量平均分子量大於6,000時,會因黏度過高而使交聯反應的操作產生困難,但是若添加溶劑以降低黏度進行操作,則可能導致溶劑殘留於敷料上而有細胞毒性的風險。另外,透明質酸的重量平均分子量範圍較佳500,000~2,500,000。若透明質酸的重量平均分子量大於2,500,000時,較不利於傷口癒合。 Among them, the polyisocyanate is preferably an aliphatic polyisocyanate to avoid a risk of toxicity which may be selected from an aromatic compound, and more preferably, the aliphatic polyisocyanate may be selected from hexamethylene diisocyanate (hexamethylene diisocyanate, HDI), methylene dicyclohexyl diisocyanate (H 12 MDI), isophorone diisocyanate (IPDI) or a combination thereof. Further, the weight average molecular weight of the polydiethanol is preferably in the range of 1,000 to 6,000. If the weight average molecular weight of the polyethylene glycol is less than 1,000, biotoxicity is generated via metabolism; if the weight average molecular weight of the polyethylene glycol is more than 6,000, the operation of the crosslinking reaction may be difficult due to the high viscosity, but if Adding a solvent to lower the viscosity allows the solvent to remain on the dressing and pose a risk of cytotoxicity. Further, the weight average molecular weight of hyaluronic acid is preferably in the range of 500,000 to 2,500,000. If the weight average molecular weight of hyaluronic acid is more than 2,500,000, it is not conducive to wound healing.
進一步,將親水性聚氨酯與發泡組分進行發泡反應以形成親水性聚氨酯發泡體100。其中,該發泡組份可包含發泡劑、水、界面活性劑、多胺及催化劑。其中,多胺係用以增加親水性聚氨酯的機械強度,更佳地,多胺是選自於1,2-乙二胺、1,4-丁二胺、1,6-己二胺、三伸乙四胺(triethylenetetramine,TETA)或聚醚胺(polyetheramine)。聚醚胺可選自但不限於Huntsman公司生產的JEFFAMINE®。催化劑係用以催化過量的多異氰酸酯與水反應產生二氧化碳, 更佳地,催化劑可選自於異辛酸鋅、三伸乙二胺(TEDA,DABCO)、二甲基環己胺(DMCHA)、二甲基乙醇胺(DMEA)、三乙胺(TEA)、1,8-二吖雙環[5.4.0]十一-7-烯(DBU)或五甲基二伸乙三胺(pentamethyldiethylenetriamine,PMDETA)。 Further, the hydrophilic polyurethane and the foaming component are subjected to a foaming reaction to form a hydrophilic polyurethane foam 100. Wherein, the foaming component may comprise a blowing agent, water, a surfactant, a polyamine and a catalyst. Wherein, the polyamine is used to increase the mechanical strength of the hydrophilic polyurethane, and more preferably, the polyamine is selected from the group consisting of 1,2-ethanediamine, 1,4-butanediamine, 1,6-hexanediamine, and three Triethylenetetramine (TETA) or polyetheramine. Polyetheramine selected from, but not limited to, produced by Huntsman JEFFAMINE ®. The catalyst is used to catalyze the reaction of excess polyisocyanate with water to produce carbon dioxide. More preferably, the catalyst may be selected from the group consisting of zinc isooctanoate, triethylene glycol diamine (TEDA, DABCO), dimethylcyclohexylamine (DMCHA), Methylethanolamine (DMEA), triethylamine (TEA), 1,8-dioxinbicyclo[5.4.0]undec-7-ene (DBU) or pentamethyldiethylenetriamine (PMDETA).
值得一提的是,親水性聚氨酯發泡體100的孔洞是藉由加入過量的多異氰酸酯與水反應而產生二氧化碳(CO2),以及與發泡劑進行發泡反應而使親水性聚氨酯自體發泡而形成。其中,多異氰酸酯的含量範圍可佔親水性聚氨酯的20~70mol%,較佳為40~50mol%。因此在親水性聚氨酯發泡體100中能形成非連續式的封閉孔洞,使各孔洞之間彼此獨立。 It is worth mentioning that the pores of the hydrophilic polyurethane foam 100 are produced by reacting an excess of polyisocyanate with water to produce carbon dioxide (CO 2 ), and foaming reaction with a foaming agent to make the hydrophilic polyurethane self-contained. Formed by foaming. The content of the polyisocyanate may range from 20 to 70 mol%, preferably from 40 to 50 mol%, of the hydrophilic polyurethane. Therefore, in the hydrophilic polyurethane foam 100, discontinuous closed pores can be formed so that the respective pores are independent of each other.
在下文中,將參照以下合成例及應用例更詳細描述本發明之溼式創傷敷料,並將以下應用例及比較例進行傷口癒合測試。 Hereinafter, the wet wound dressing of the present invention will be described in more detail with reference to the following Synthesis Examples and Application Examples, and the following application examples and comparative examples are subjected to a wound healing test.
〔合成例1〕星狀親水性聚氨酯PU1 [Synthesis Example 1] Star-shaped hydrophilic polyurethane PU1
將1mol PPG6000 triol(重量平均分子量為6,000)與3mol HDI混合,在80℃下反應1小時,以得到星狀預聚物之後,再加入1mol PEG1000(重量平均分子量為1,000)、1.5mol PEG2000(重量平均分子量為2,000)及0.5mol透明質酸(重量平均分子量為1,000,000),在80℃下進行交聯反應6小時,得到星狀親水性聚氨酯PU1。 1 mol of PPG6000 triol (weight average molecular weight of 6,000) was mixed with 3 mol of HDI, and reacted at 80 ° C for 1 hour to obtain a star-shaped prepolymer, and then 1 mol of PEG 1000 (weight average molecular weight of 1,000) and 1.5 mol of PEG 2000 (weight) were added. The average molecular weight was 2,000) and 0.5 mol of hyaluronic acid (weight average molecular weight: 1,000,000), and the crosslinking reaction was carried out at 80 ° C for 6 hours to obtain a star-shaped hydrophilic polyurethane PU1.
〔合成例2〕星狀親水性聚氨酯PU2 [Synthesis Example 2] Star-shaped hydrophilic polyurethane PU2
將0.5mol PPG6000 triol與2.5mol HDI混合,在80℃下反應1小時,以得到星狀預聚物之後,再加入0.85mol PEG1000、0.85mol PEG2000及0.1mol透明質酸(重量平均分子量為1,000,000),在80℃下進行交聯反應6小時,得到星狀親水性聚氨酯PU2。 0.5 mol of PPG6000 triol was mixed with 2.5 mol of HDI, and reacted at 80 ° C for 1 hour to obtain a star-shaped prepolymer, and then 0.85 mol of PEG 1000, 0.85 mol of PEG 2000 and 0.1 mol of hyaluronic acid (weight average molecular weight of 1,000,000) were further added. The crosslinking reaction was carried out at 80 ° C for 6 hours to obtain a star-shaped hydrophilic polyurethane PU 2 .
〔應用例1〕溼式創傷敷料DR1 [Application Example 1] Wet wound dressing DR1
將合成例1的星狀親水性聚氨酯PU1與1mol HDI混合攪拌之後,塗佈於一離型膜上,在120℃下加熱1小時,得到本發明的溼式創傷敷料DR1。 The star-shaped hydrophilic polyurethane PU1 of Synthesis Example 1 and 1 mol of HDI were mixed and stirred, and then applied onto a release film, and heated at 120 ° C for 1 hour to obtain a wet wound dressing DR1 of the present invention.
〔應用例2〕溼式創傷敷料DR2 [Application Example 2] Wet wound dressing DR2
將0.1mol碳酸氫鈉(發泡劑)、0.4mol水、0.5mol聚二甲矽氧烷-聚氧化烯共聚物(界面活性劑)、0.1mol乙二胺及0.1mol異辛酸鋅(催化劑,購自於台灣錫生金化學工業股份有限公司,型號為TMG620)混合得到一發泡組分,接著將合成例2的星狀親水性聚氨酯PU2與該發泡組分快速攪拌混合,發泡成形後得到親水性聚氨酯發泡體100,且該發泡體100的孔洞為非連續式的封閉孔洞。接著參照第2圖,將該親水性聚氨酯發泡體100裁切成適當大小,並將其固著於具有黏性的背襯300上,再將離型紙301覆蓋親水性聚氨酯發泡體100及背襯300上,以得到應用例2的溼式創傷敷料DR2。 0.1 mol of sodium hydrogencarbonate (foaming agent), 0.4 mol of water, 0.5 mol of polydimethyloxane-polyoxyalkylene copolymer (surfactant), 0.1 mol of ethylenediamine and 0.1 mol of zinc isooctylate (catalyst, It was purchased from Taiwan Tin Sangjin Chemical Industry Co., Ltd., model TMG620) to obtain a foaming component, and then the star-shaped hydrophilic polyurethane PU2 of Synthesis Example 2 was rapidly stirred and mixed with the foaming component to form a foamed molding. Thereafter, a hydrophilic polyurethane foam 100 is obtained, and the pores of the foam 100 are discontinuous closed pores. Next, referring to Fig. 2, the hydrophilic polyurethane foam 100 is cut into an appropriate size, and fixed to the viscous backing 300, and the release paper 301 is covered with the hydrophilic polyurethane foam 100 and The backing 300 was applied to obtain the wet wound dressing DR2 of Application Example 2.
〔比較例1〕創傷敷料CDR1 [Comparative Example 1] Wound dressing CDR1
比較例1的創傷敷料CDR1為一般紗布。 The wound dressing CDR1 of Comparative Example 1 was a general gauze.
〔比較例2〕創傷敷料CDR2 [Comparative Example 2] Wound dressing CDR2
比較例2的創傷敷料CRD2為3M公司市售的柔軟傷口敷料3662A,其與傷口接觸的材質為不織布。 The wound dressing CRD2 of Comparative Example 2 was a soft wound dressing 3662A commercially available from 3M Company, and the material in contact with the wound was a non-woven fabric.
〔比較例3〕溼式創傷敷料CDR3 [Comparative Example 3] Wet wound dressing CDR3
比較例3的溼式創傷敷料CDR3為AMED公司市售的水膠傷口敷料HERADERA®,其與傷口接觸的材質為2-羥乙基甲基丙烯酸甲酯(HEMA)。 The wet wound dressing CDR3 of Comparative Example 3 was a commercially available water gel wound dressing HERADERA ® from AMED, and the material in contact with the wound was 2-hydroxyethyl methyl methacrylate (HEMA).
〔傷口癒合測試〕 [Wound healing test]
A.實驗動物 A. Experimental animals
下面實驗中使用雄性的S.D.大鼠(Sprague-Dawley rats,S.D.rats)(8週大,體重約200g。所有實驗動物飼養於光照週期分別為光照與黑暗各12小時、室溫維持於22℃及相對溼度維持在42%的獨立空調的動物房內,且充分供給水及飼料。在實驗之前,給予動物至少2週的適應環境。有關實驗動物的飼養環境、處理及所有實驗程序均符合國家衛生研究院(National Institutes of Health,NIH)的實驗動物飼養管理及使用規範(Guide for the Care and Use of Laboratory Animals)。 In the following experiments, male SD rats (Sprague-Dawley rats, SDrats) were used (8 weeks old, weighing about 200 g. All experimental animals were kept in the light cycle for 12 hours for light and dark, and 22 °C for room temperature, respectively. The relative humidity is maintained in 42% of the independent air-conditioned animal room, and the water and feed are fully supplied. Before the experiment, the animals are given at least 2 weeks to adapt to the environment. The breeding environment, treatment and all experimental procedures of the experimental animals are in line with national health. National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.
B.生物纖維敷料的滅菌(sterilization): B. Sterilization of biofiber dressings:
將上述應用例1、2及比較例1中所得到的創傷敷料DR1、DR2及CDR1以珈瑪射線(γ-ray)(劑量為40kGy)予以滅菌,接著進行下述的實驗。 The wound dressings DR1, DR2 and CDR1 obtained in the above Application Examples 1 and 2 and Comparative Example 1 were sterilized by gamma ray (dose of 40 kGy), followed by the following experiment.
C.皮膚傷口(skin wound)的形成: C. Formation of skin wounds:
將S.D.大鼠的背側部分(dorsal part)進行剃毛(shaving),接著以碘酒(tincture of iodine)以及70%酒精予以消毒(disinfected)之後,使用手術刀(surgical knife)於S.D.大鼠的背部的左側切出具有一約為2cm×2cm的面積大小以及約為2~3mm的深度的皮膚傷口。 The dorsal part of the SD rat was shaved, followed by disinfected with tincture of iodine and 70% alcohol, and then a surgical knife was used for the SD rat. The left side of the back is cut out to have a skin size of about 2 cm x 2 cm and a depth of about 2 to 3 mm.
D.敷料的施用: D. Application of dressing:
S.D.大鼠被隨機地分成2個實驗組以及3個對照組(亦即,實驗組1、2及對照組1~3)(每組n=3),其中各組的S.D.大鼠是依照上述第C項所述的方法形成皮膚傷口。接著,實驗組1及2的S.D.大鼠的皮膚傷口分別被施用根據上述第B項所製得之經滅菌的溼式創傷敷料DR1及DR2,而對照組1、2及3的S.D.大鼠的皮膚傷口分別施用根據上述第B項所製得之經滅菌的創傷敷料CDR1、創傷敷料CDR2及溼式創傷敷料CDR3。實驗總共進行7天,在施用敷料之後的第1、3、5及7天,分別對測量各組S.D.大鼠的傷口面積,其結果如表1所示。 SD rats were randomly divided into two experimental groups and three control groups (ie, experimental group 1, 2 and control group 1-3) (n=3 per group), in which SD rats of each group were in accordance with the above The method of item C forms a skin wound. Next, the skin wounds of the SD rats of the experimental groups 1 and 2 were administered with the sterilized wet wound dressings DR1 and DR2 prepared according to the above item B, respectively, while the SD rats of the control groups 1, 2 and 3 were administered. The dermal wounds were separately applied with the sterilized wound dressing CDR1, the wound dressing CDR2 and the wet wound dressing CDR3 prepared according to item B above. The experiment was carried out for a total of 7 days, and the wound areas of each group of S.D. rats were measured on days 1, 3, 5 and 7 after the application of the dressing, and the results are shown in Table 1.
如表1所示,在施用敷料後第1天至第7天,實驗組1及2的S.D.大鼠的皮膚傷口的面積皆明顯縮小,其中,實驗組2的S.D.大鼠的皮膚傷口在施用敷料後第7天接近完全癒合,而對照組1至3的S.D.大鼠的皮膚傷口的面積縮小速度則明顯較緩慢,顯示實驗組1及2的溼式創傷敷料DR1及DR2與對照組1~3的創傷敷料CDR1~CDR3相比具有顯著較佳的傷口癒合效果。 As shown in Table 1, the skin wound area of the SD rats of the experimental groups 1 and 2 was significantly reduced from the first day to the seventh day after the application of the dressing, wherein the skin wound of the SD rats of the experimental group 2 was applied. On the 7th day after the dressing, the skin was nearly completely healed, while the skin wound area of the SD rats of the control group 1 to 3 was significantly slower, showing the wet wound dressings DR1 and DR2 of the experimental groups 1 and 2 and the control group 1~ The wound dressings of CDR1 to CDR3 of 3 have significantly better wound healing effects.
根據本發明之第一實施例,本發明之溼式創傷敷料能藉由比表面積較大的星狀嵌段聚氨酯提升創傷敷料的吸水性,因此能吸收過多的組織液而避免細胞浸潤。並且,藉由非連續式的封閉孔洞及聚乙二醇具有抗蛋白質及細胞貼附的特性,能使增生的細胞不會進入創傷敷料,而達到防止傷口沾黏的效果。此外,本發明之溼式創傷敷料不含有可能具有毒性的單體或交聯劑,故亦具有生物安全性。 According to the first embodiment of the present invention, the wet wound dressing of the present invention can enhance the water absorption of the wound dressing by the star-shaped block polyurethane having a large specific surface area, and thus can absorb excessive tissue fluid to avoid cell infiltration. Moreover, by means of discontinuous closed pores and polyethylene glycol having anti-protein and cell attachment properties, the proliferating cells can not enter the wound dressing, thereby preventing the wound from sticking. In addition, the wet wound dressing of the present invention is biosafety since it does not contain monomers or crosslinkers which may be toxic.
請一併參閱第3圖至第6圖,第3圖係為本發明之溼式創傷敷料的第二實施例之截面圖,且第4圖至第6圖係為形成第3圖所示第二實施例的階段之截面圖。在本發明的第二實施例中,溼式創傷敷料係包含親水性聚氨酯發泡體100及透氣層200。其中,親水性聚氨酯發泡體100進一步包含接觸層110與吸收層120,且接觸層110與吸收層120係為一體成形。如第3圖所示,接觸層110具有 複數個第一孔洞111,且其一面與傷口W接觸。吸收層120位在接觸層110的另一面上,且具有大於複數個第一孔洞111的複數個第二孔洞121。透氣層200係由親水性聚氨酯形成,且位在吸收層120上。 Please refer to FIG. 3 to FIG. 6 together. FIG. 3 is a cross-sectional view showing a second embodiment of the wet wound dressing of the present invention, and FIG. 4 to FIG. 6 are the drawings shown in FIG. A cross-sectional view of the stage of the second embodiment. In a second embodiment of the invention, the wet wound dressing comprises a hydrophilic polyurethane foam 100 and a gas permeable layer 200. The hydrophilic polyurethane foam 100 further includes a contact layer 110 and an absorbing layer 120, and the contact layer 110 and the absorbing layer 120 are integrally formed. As shown in FIG. 3, the contact layer 110 has A plurality of first holes 111 are formed, and one side thereof is in contact with the wound W. The absorbing layer 120 is located on the other side of the contact layer 110 and has a plurality of second holes 121 larger than the plurality of first holes 111. The gas permeable layer 200 is formed of a hydrophilic polyurethane and is positioned on the absorbent layer 120.
詳細而言,如第4圖所示,將1mol第一聚醚多元醇與3mol多異氰酸酯混合,在70℃下反應2小時,以得到預聚物之後,再加入3mol第二聚醚多元醇,在40℃下進行反應0.1小時,以得到親水性聚氨酯,並將該親水性聚氨酯製成透氣層200,例如可為聚氨酯膜,但不限於此。其中,透氣層200中的第一聚醚多元醇與第二聚醚多元醇的含量範圍可佔親水性聚氨酯的20~70mol%,較佳為40~50mol%,以形成同時具有親水端與疏水端的透氣層200,藉由親水端與疏水端彼此互斥,可產生僅容許氣體通過的氣孔,而具有良好的透氣性。並且,氣孔的尺寸可小於水分子,因此水分子無法進入透氣層200,而能達到防水且抑制微生物的生長的效果,以避免外源性的感染。 In detail, as shown in Fig. 4, 1 mol of the first polyether polyol was mixed with 3 mol of polyisocyanate, and reacted at 70 ° C for 2 hours to obtain a prepolymer, and then 3 mol of a second polyether polyol was added. The reaction was carried out at 40 ° C for 0.1 hour to obtain a hydrophilic polyurethane, and the hydrophilic polyurethane was made into a gas permeable layer 200, for example, a polyurethane film, but is not limited thereto. The content of the first polyether polyol and the second polyether polyol in the gas permeable layer 200 may range from 20 to 70 mol%, preferably 40 to 50 mol%, of the hydrophilic polyurethane to form a hydrophilic end and a hydrophobic portion. The gas permeable layer 200 at the end, by mutually repelling the hydrophilic end and the hydrophobic end, can produce pores which only allow gas to pass through, and has good gas permeability. Moreover, the size of the pores can be smaller than that of the water molecules, so that the water molecules cannot enter the gas permeable layer 200, and the effect of waterproofing and inhibiting the growth of microorganisms can be achieved to avoid exogenous infection.
接著如第5圖所示,將1mol第一聚醚多元醇與3mol多異氰酸酯混合,在70℃下反應2小時,以得到星狀預聚物,接著加入3mol第二聚醚多元醇,並在40℃下進行反應0.1小時,以得到星狀親水性聚氨酯,將上述的4mol的星狀親水性聚氨酯與發泡組分快速攪拌混合後塗佈在透氣層200上,而使親水性聚氨酯發泡體100與透氣層200一體成形。其中,親水性聚氨酯發泡體100的孔洞為非連續式的封閉孔洞,且其中的第一聚醚多元醇與第二聚醚多元醇的含量範圍係佔親水性聚氨酯的20~70mol%,較佳為40~50mol%。 Next, as shown in Fig. 5, 1 mol of the first polyether polyol was mixed with 3 mol of polyisocyanate, and reacted at 70 ° C for 2 hours to obtain a star-shaped prepolymer, followed by the addition of 3 mol of the second polyether polyol, and The reaction was carried out at 40 ° C for 0.1 hour to obtain a star-shaped hydrophilic polyurethane, and the above-mentioned 4 mol of the star-shaped hydrophilic polyurethane and the foaming component were rapidly stirred and mixed, and then coated on the gas permeable layer 200 to foam the hydrophilic polyurethane. The body 100 is integrally formed with the gas permeable layer 200. Wherein, the pore of the hydrophilic polyurethane foam 100 is a discontinuous closed pore, and the content of the first polyether polyol and the second polyether polyol is 20 to 70 mol% of the hydrophilic polyurethane. Good is 40~50mol%.
進一步,如第6圖所示,在形成親水性聚氨酯發泡體100時(發泡反應完成之前),在該親水性聚氨酯發泡體100的表面上以例如進行刮動的動作,但不限於此,並且在其上施加100~300g/cm2的壓力,較佳為 120~250g/cm2的壓力,以壓縮親水性聚氨酯發泡體100表面在進行發泡反應時所產生的氣泡,因而在發泡體100的表面上形成具有孔徑較小的第一孔洞111的接觸層110,且第一孔洞111以小於細胞的尺寸為較佳,例如其直徑可為40~140μm,較佳為40~60μm,而吸收層120形成在接觸層110與透氣層200之間,且具有相對於第一孔洞111較大的第二孔洞121,其直徑可為100~1000μm,較佳為400~800μm。其中,接觸層110所形成的厚度可佔親水性聚氨酯發泡體100整體厚度的0.1~5%,較佳為0.1~1%。 Further, as shown in Fig. 6, when the hydrophilic polyurethane foam 100 is formed (before the completion of the foaming reaction), the surface of the hydrophilic polyurethane foam 100 is, for example, subjected to a scraping operation, but is not limited thereto. And applying a pressure of 100 to 300 g/cm 2 , preferably 120 to 250 g/cm 2 , to compress the bubbles generated when the surface of the hydrophilic polyurethane foam 100 is subjected to a foaming reaction, thereby A contact layer 110 having a first hole 111 having a small aperture is formed on the surface of the foam 100, and the first hole 111 is preferably smaller than the size of the cell, for example, the diameter may be 40 to 140 μm, preferably 40. The absorber layer 120 is formed between the contact layer 110 and the gas permeable layer 200, and has a second hole 121 which is larger than the first hole 111 and has a diameter of 100 to 1000 μm, preferably 400 to 800 μm. The thickness of the contact layer 110 may be 0.1 to 5%, preferably 0.1 to 1%, of the entire thickness of the hydrophilic polyurethane foam 100.
值得一提的是,接觸層110藉由小於細胞尺寸的非連續式封閉孔洞及具有抗蛋白質及細胞貼附特性的聚乙二醇,能避免傷口W中的增生細胞進入接觸層110,而能達到防止傷口沾黏的效果。另外,藉由吸收層120的第二孔洞121能吸收大量的組織液,同時使傷口W維持在適當的濕潤環境但不會造成傷口浸潤,進而加速纖維母細胞移動以促進血管生成並增加分解死亡組織和纖維蛋白的速度。並且,藉由第二孔洞121吸收組織液之後產生膨脹形變而緊貼傷口W及皮膚S,能抑制纖維母細胞癒合時向傷口W中心收縮,以預防疤痕的產生。 It is worth mentioning that the contact layer 110 can prevent the proliferating cells in the wound W from entering the contact layer 110 by using a discontinuous closed pore smaller than the cell size and polyethylene glycol having anti-protein and cell attachment properties. Achieve the effect of preventing the wound from sticking. In addition, the second hole 121 of the absorbing layer 120 can absorb a large amount of tissue fluid while maintaining the wound in a proper moist environment without causing wound infiltration, thereby accelerating the movement of the fibroblast to promote angiogenesis and increase decomposition of dead tissue. And the speed of fibrin. Further, the second pore 121 absorbs the tissue fluid and then expands and deforms to adhere to the wound W and the skin S, thereby suppressing the contraction of the fibroblast to the center of the wound W to prevent the occurrence of scars.
綜上所述,本發明之溼式創傷敷料可藉由材料中同時包含親水端及疏水端的特性而具有良好的透氣性,並且利用星狀聚氨酯具有良好的吸水性,能避免傷口浸潤,進而使傷口能保持在適當的溼潤環境。此外,接觸層能利用聚乙二醇的特性及小於細胞尺寸的非連續式封閉孔洞,達到防止傷口沾黏的效果。藉此,本發明之溼式創傷敷料通常可連續使用7至14天而不會干擾自體清創,以加速傷口的癒合。 In summary, the wet wound dressing of the present invention can have good gas permeability by the property of containing both a hydrophilic end and a hydrophobic end in the material, and the star-shaped polyurethane has good water absorption, can avoid wound infiltration, and thus The wound can be kept in a proper moist environment. In addition, the contact layer can utilize the characteristics of polyethylene glycol and the discontinuous closed pores smaller than the cell size to prevent the wound from sticking. Thereby, the wet wound dressing of the present invention can generally be used continuously for 7 to 14 days without interfering with autologous debridement to accelerate wound healing.
以上所述僅為舉例性,而非為限制性者。任何未脫離本發明之精神與範疇,而對其進行之等效修改或變更,均應包含於後附之申請專利範圍中。 The above is intended to be illustrative only and not limiting. Any equivalent modifications or alterations to the spirit and scope of the invention are intended to be included in the scope of the appended claims.
100‧‧‧親水性聚氨酯發泡體 100‧‧‧Hydrophilic polyurethane foam
110‧‧‧接觸層 110‧‧‧Contact layer
111‧‧‧第一孔洞 111‧‧‧First hole
120‧‧‧吸收層 120‧‧‧absorbing layer
121‧‧‧第二孔洞 121‧‧‧Second hole
200‧‧‧透氣層 200‧‧‧ breathable layer
S‧‧‧皮膚 S‧‧‧ skin
W‧‧‧傷口 W‧‧‧Wound
Claims (8)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW105102408A TWI592173B (en) | 2016-01-26 | 2016-01-26 | Wet wound dressing |
| US15/149,556 US20160331860A1 (en) | 2015-05-12 | 2016-05-09 | Wet wound dressing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW105102408A TWI592173B (en) | 2016-01-26 | 2016-01-26 | Wet wound dressing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TWI592173B true TWI592173B (en) | 2017-07-21 |
| TW201726186A TW201726186A (en) | 2017-08-01 |
Family
ID=60048489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105102408A TWI592173B (en) | 2015-05-12 | 2016-01-26 | Wet wound dressing |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI592173B (en) |
-
2016
- 2016-01-26 TW TW105102408A patent/TWI592173B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201726186A (en) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11648333B2 (en) | Medical dressing | |
| AU2015314265B2 (en) | Medical dressing | |
| JP6705888B2 (en) | Antibacterial dressing and manufacturing method thereof | |
| TWI465263B (en) | Medical dressing and negative pressure wound therapy apparatus using the same | |
| EP1964580B1 (en) | Silver-containing foam structure | |
| TWI597075B (en) | Hydrophilic polyurethane, hydrophilic polyurethane foam and its preparation Wet wound dressing | |
| US10953127B2 (en) | Absorbent foam wound dressing materials | |
| WO1992019194A1 (en) | Wound covering material | |
| NO304816B1 (en) | Wound dressing containing polyurethane foam and manufacture thereof | |
| US20160331860A1 (en) | Wet wound dressing | |
| KR20200013449A (en) | Polyurethane foam dressing comprising silver-activated carbon composites and producing method thereof | |
| JP5020639B2 (en) | Medicinal polyurethane foam | |
| KR101879643B1 (en) | Spray-type soft-melting polyurethane foam wound dressing and producing method thereof | |
| TWI592173B (en) | Wet wound dressing | |
| TWM513030U (en) | Wet wound dressing | |
| TWI597080B (en) | Negative pressure treatment device | |
| JPWO1992019194A1 (en) | wound dressing | |
| TWM514854U (en) | Negative pressure wound therapy apparatus |